focus -WSS

focus

author：comprehensive 2025-09-07 04:06:38 - browse：6

The Food and Drug Administration on Friday approved the world’s first medicine based on CRISPR gene-editing technology, a groundbreaking treatment for sickle cell disease that delivers a potential cure for people born with the chronic and life-shortening blood disorder.

The new medicine, called Casgevy, is made by Vertex Pharmaceuticals and CRISPR Therapeutics. Its authorization is a scientific triumph for the technology that can efficiently and precisely repair DNA mutations — ushering in a new era of genetic medicines for inherited diseases.

In a clinical trial, Casgevy was shown to eliminate recurrent episodes of debilitating pain caused by sickle cell, which afflicts approximately 100,000 people in the U.S., a vast majority of whom are Black. The therapy, whose scientific name is exa-cel, is described as a potential cure because the genetic fix enabled by CRISPR is designed to last a lifetime, although confirmation will require years of follow-up.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： White House calls on federal agencies to crack down on AI abuses

WSS

HPV cancer vaccine study demonstrates efficacy

Emergency workers more likely to restrain Black patients: study

Biotech lab space demand falls sharply

Why are Kaiser Permanente staff considering a strike?

STAT Virtual Event: Putting AI to the Test

STAT Executive Editor Rick Berke on STAT's 8th birthday

leisure time

focus

focus

Medicare details structure of new drug price negotiation program

HPV cancer vaccine study demonstrates efficacy

Cancer drug shortages should be causing more outrage

STAT Executive Editor Rick Berke on STAT's 8th birthday

DIEP, the 'gold standard' of breast reconstruction, is under threat

Experts study whether long Covid risk adds up with each reinfection

Medicare details structure of new drug price negotiation program

FDA approves Recor Medical high blood pressure device

Apple is now the first public company to be valued at $3 trillion

Senate panel clears PBM, hopsital reforms

leisure time

Medical student insurance fails on mental health care coverage

CDC's new outbreak response network to include Northeastern

Study: New antibiotic targets gonorrhea as well as last existing drug

MoonLake credibility takes another hit with mid

FDA approves Recor Medical high blood pressure device

Extreme heat events are a public health emergency

leisure time

focus

hotspot

leisure time